Betaine and Nonalcoholic Steatohepatitis [2]

American Journal of Gastroenterology

Volumn 98, Issue 12, 2003, Pages 2803-

  Houghton, William C ^a  

^a JAZZ PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BETAINE; COBALAMIN; CYSTATHIONINE BETA SYNTHASE; HOMOCYSTEINE;

CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; HOMOCYSTINURIA; HUMAN; LETTER; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

EID: 0347364705     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.08689.x     Document Type: Letter

References (7)

1. Mailliard M. What is betaine and why could it prevent liver damage? Cytoprotection and the liver. Am J Gastroenterol 2003;98:726.
2. Abdelmalek MF, Angula P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis. Results of a pilot study. Am J Gastroenterol 2001;96:2711-7.
3. Barak AJ, Beckenhauer HC, Badakhsh S, et al. The effect of betaine in reversing alcoholic steatosis. Alcohol Clin Exp Res 1997;21:1100-2.
4. Graf D, Kurz AK, Reinehr, et al. Prevention of bile acid-induced apoptosis by betaine in rat liver. Hepatology 2002;36:829-39.
5. US Department of Health and Human Services, Center for Food Safety and Applied Nutrition. Dietary supplements. Available at: http://vm.cfsan.fda.gov/~dms/supplmnt.html. Accessed August 27, 2003.
6. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed, vol 2. New York: McGraw-Hill, 2001:1278-327.
7. Rosenblatt DS, Fenton WA. Inherited disorders of folate and cobalamin transport and metabolism. In: Scriver CR, Beaudet Al, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 2001:3897-933.